On September 7, 2026 Nerviano Medical Sciences S.r.l. ("NMS"), a global oncology-focused biopharmaceutical company, reported its participation in the upcoming World Conference on Lung Cancer ("WCLC") of the International Association for the Study of Lung Cancer ("IASLC"), taking place in Seoul, Republic of Korea, from September 12 to 15, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At the meeting, NMS will present a scientific poster featuring its proprietary PARP7 inhibitor, atamparib.
Title: "A Phase Ib/II Study of Atamparib, a PARP7 Inhibitor, in Patients with Advanced Solid Tumors"
Presenter: Dr. Xinru Chen, Shanghai East Hospital
Poster Section: Clinical Trials in Progress
Poster Board Number: P2-372
Abstract Control Number: 606
Date & Time: Monday, September 14, 2026 at 10:30 AM KST / UTC +9
Link to full poster abstract: View Source
This ongoing phase 1b/2 trial is evaluating atamparib, a potential, orally bioavailable, selective PARP7 inhibitor. Through its unique dual mechanism of action, atamparib disrupts KRAS-driven and other oncogenic signaling pathways, while activating innate immune responses. The study is currently exploring higher dose levels and generating proof-of-concept data in selected patients with advanced or metastatic NSCLC adenocarcinoma.
We look forward to engaging with the scientific community at the IASLC 2026 WCLC and sharing insights from our work.
About Atamparib
Atamparib was acquired by NMS from Ribon Therapeutics in November 2024 (previously RBN 2397/ONO 7119). It has demonstrated a favorable tolerability profile in prior Phase I/II clinical evaluation (NCT04053673, NCT05127590, JRCT2031210373). Supported by new preclinical data and early signs of clinical activity, NMS is advancing atamparib for the treatment of advanced or metastatic solid tumors, with the goal of addressing significant unmet medical needs as a single agent and in combination regimens.
20260912-NMS WCLC Poster Presentation
(Press release, Nerviano Medical Sciences, SEP 7, 2026, View Source [SID1234670609])